ClinicalTrials.gg
CompletedNCT00085943Updated May 16, 2011

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

A Phase 3 interventional study of LEXIVA (GW433908) and Ritonavir in HIV Infection and Infection, Human Immunodeficiency Virus, sponsored by GlaxoSmithKline. Completed at 120 sites in 14 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-05-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
866
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing fosamprenavir in HIV Infections — none open to participants now, none under way, none of them phase 3. fosamprenavir · HIV Infections.

Enrollment
Largest of 13
866 · median 63
Started
2004
with 1 other
Phase 3
5 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
3 of 13
GlaxoSmithKline

Among the 13 studies testing fosamprenavir in HIV Infections, this one has the largest enrollment, is one of 2 that started in 2004, is one of 5 in phase 3, and was the 6th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 13 studies testing fosamprenavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About fosamprenavir

fosamprenavir: first FDA approval 2003 (LEXIVA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing fosamprenavir in HIV Infections as a file.
02

Study summary

This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.

Read the detailed description

A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks

03

Conditions studied

  • HIV Infection
  • Infection, Human Immunodeficiency Virus

Keywords

  • ritonavir
  • abacavir
  • HIV
  • lopinavir
  • lamivudine
  • fosamprenavir
  • Epzicom
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infected subjects that are naive to anti-HIV therapy.
  • History of a positive HIV test.
  • At least 1000 copies/mL of HIV in their blood as screening.

Exclusion criteria

Exclusion Criteria:

  • Active -related diseases.
  • Taking other drugs.
  • Pregnant or breastfeeding females.
  • Not be suitable to participate per investigator opinion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
866 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with plasma HIV-1 RNA <400 copies/mL at Week 48. Proportion of subjects who permanently discontinue randomized treatment due to adverse events.

Secondary outcomes

  1. Proportion of subjects with plasma HIV-1 RNA <400 copies/mL at Week 48. Proportion of subjects who permanently discontinue randomized treatment due to adverse events.

07

Study locations

120 sites
  • GSK Investigational Site
    Birmingham, Alabama 35233, United States
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Los Angeles, California 90046, United States
  • GSK Investigational Site
    Sacramento, California 95825, United States
  • GSK Investigational Site
    San Francisco, California 94115-1931, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20036, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Bradenton, Florida 34205, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33024, United States
  • GSK Investigational Site
    Tampa, Florida 33602, United States
  • GSK Investigational Site
    Tampa, Florida 33607, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30339, United States
  • GSK Investigational Site
    Chicago, Illinois 60612-7230, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Chicago, Illinois 60613, United States
  • GSK Investigational Site
    Chicago, Illinois 60657, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46280, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Boston, Massachusetts 02118, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08876, United States
  • GSK Investigational Site
    Newark, New Jersey 07103, United States
  • GSK Investigational Site
    Somers Point, New Jersey 08244, United States
  • GSK Investigational Site
    Voorhees, New Jersey 08043, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Bronx, New York 10468, United States
  • GSK Investigational Site
    New York, New York 10014, United States
  • GSK Investigational Site
    Rochester, New York 14620, United States
  • GSK Investigational Site
    Stony Brook, New York 11794-8091, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27516, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Greenville, North Carolina 27858, United States
  • GSK Investigational Site
    Toledo, Ohio 43614-5809, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Columbia, South Carolina 29206-4713, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37920, United States
  • GSK Investigational Site
    Dallas, Texas 75208, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Hampton, Virginia 23666, United States
  • GSK Investigational Site
    Lynchburg, Virginia 24501, United States
  • GSK Investigational Site
    Seattle, Washington 98101, United States
  • GSK Investigational Site
    Seattle, Washington 98104, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Vienna, A-1090, Austria
  • GSK Investigational Site
    Bruxelles, 1000, Belgium
  • GSK Investigational Site
    Charleroi, 6000, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Liege, 4000, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Calgary, Alberta T2P 1H9, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1N 6N5, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M4T 3A7, Canada
  • GSK Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • GSK Investigational Site
    Bordeaux Cedex, 33076, France
  • GSK Investigational Site
    Le Kremlin Bicêtre Cedex, 94275, France
  • GSK Investigational Site
    Lyon Cedex 02, 69288, France
  • GSK Investigational Site
    Lyon Cedex 03, 69437, France
  • GSK Investigational Site
    Paris Cedex 10, 75475, France
  • GSK Investigational Site
    Paris Cedex 13, 75651, France
  • GSK Investigational Site
    Paris Cedex 14, 75679, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Saint Denis Cedex 01, 93205, France
  • GSK Investigational Site
    Fuerth, Bayern 90762, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80331, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 20099, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Ferrara, Emilia-Romagna 44100, Italy
  • GSK Investigational Site
    Modena, Emilia-Romagna 41100, Italy
  • GSK Investigational Site
    Rimini, Emilia-Romagna 47900, Italy
  • GSK Investigational Site
    Busto Arsizio (VA), Lombardia 21052, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Torino, Piemonte 10149, Italy
  • GSK Investigational Site
    Riga, LV 1006, Latvia
  • GSK Investigational Site
    Luxembourg, 1210, Luxembourg

Showing the first 100 of 120 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Eron J Jr, Yeni P, Gathe J Jr, Estrada V, DeJesus E, Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J, Shaefer M; KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006 Aug 5;368(9534):476-82. doi: 10.1016/S0140-6736(06)69155-1. Erratum In: Lancet. 2006 Oct 7;368(9543):1238. PubMed 16890834 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00085943
Lead sponsor
GlaxoSmithKline
First posted
Jun 21, 2004
Start date
May 2004
Last update
May 16, 2011

Study contacts

GSK Clinical Trials, Pharm.D.
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fosamprenavir · Ritonavir · Lamivudine

Start the discussion